Why You Should Avoid Palantir and Buy These 2 Defense Stocks Instead

RTX carries a $289 billion backlog, including $119 billion in defense, while Raytheon Q2 2026 sales rose 18% year over year to $8.3 billion, underscoring strong demand for air defense, missiles and radar systems. Northrop Grumman reported a $104.7 billion backlog after $20 billion of Q2 net awards, supported by multidecade B-21 bomber and Sentinel missile programs. The article favors RTX and Northrop over Palantir as more durable, lower-valuation ways to gain exposure to elevated defense spending through long-term hardware contracts.

Analysis

The relevant differentiation is not backlog size but conversion quality and execution risk. RTX’s broad missile-defense mix should translate incremental appropriations into relatively repeatable production, sustainment, and spares revenue; its commercial aerospace cash flows also diversify the defense budget cycle. NOC has greater duration but materially higher fixed-price development exposure, making B-21 and Sentinel margin performance—not award announcements—the key determinant of whether its backlog deserves a premium multiple.

PLTR’s relative vulnerability is valuation-duration mismatch: defense AI spend can grow rapidly while remaining a small share of total procurement, and software awards face shorter recompete cycles than platform programs. A rotation from AI narrative exposure into defense primes is plausible over the next 1-3 months if budget headlines improve, but it is not automatically a PLTR short: its commercial growth can decouple from Pentagon procurement and short interest/retail ownership can sustain a premium.

Near term, watch FY27 defense appropriations, supplemental funding, and Pentagon production-rate decisions. Over 6-18 months, the more important second-order constraint is the industrial base: propulsion, energetics, electronics, and skilled labor shortages can defer revenue recognition while raising working-capital needs. For RTX, Pratt & Whitney supply-chain remediation and free-cash-flow conversion remain the principal company-specific falsifiers; for NOC, any further Sentinel cost/schedule reset would overwhelm the backlog narrative.

Consensus likely overstates the defensive quality of all backlog dollars. Investors should distinguish mature replenishment programs, where RTX has operating leverage, from technically complex cost-to-complete programs, where NOC can absorb inflation and engineering overruns before realizing cash flow. The best expression is selective quality exposure rather than a wholesale long-defense/short-software trade.

Key Decisions for Investors

• Initiate/maintain overweight RTX versus NOC over the next 3-6 months; favor RTX if Raytheon segment margin and company free-cash-flow guidance are reaffirmed. Target a 8-12% relative return from mix-driven estimate revisions; exit the relative position if RTX cuts FCF guidance or Pratt remediation costs reaccelerate.
• Use a modest pair: long RTX / short PLTR, sized at low beta, into FY27 budget and appropriations catalysts over 1-3 months. The thesis is relative multiple compression if hardware production funding is prioritized; stop out if PLTR raises commercial-growth guidance materially or wins a large multi-year enterprise-scale government program that changes revenue visibility.
• Avoid adding NOC solely on strategic-program backlog. Set an alert for the next Sentinel cost estimate, EAC disclosure, and B-21 production-rate commentary; upgrade to long only if management demonstrates stable program margins and no additional charge risk. A new material cost reset is a catalyst for underperformance despite revenue visibility.
• For broader defense exposure, prefer XAR over ITA for a 6-12 month allocation if munitions replenishment broadens to suppliers; XAR has greater exposure to smaller aerospace/defense manufacturers that may see stronger incremental order growth. Reassess if appropriations are delayed beyond a continuing-resolution period, which typically pushes contract awards and production ramps rightward.